Cosmos Health Aims for $300M Stock Offering

TL;DR

Cosmos Health filing for $300M stock offering. Big pharma play incoming?

AI Summary

Cosmos Health Inc. filed an S-1 form on December 18, 2024, indicating a proposed offering of up to $300 million in common stock. The company, formerly known as Cosmos Holdings Inc. and Prime Estates & Developments Inc., is incorporated in Nevada and operates in the wholesale drug sector. The filing details various financial figures, including revenues and expenses, and outlines the intended use of proceeds from the offering.

Why It Matters

This S-1 filing signals Cosmos Health's intent to raise significant capital, which could fuel expansion or acquisitions in the pharmaceutical distribution sector.

Risk Assessment

Risk Level: medium — The S-1 filing indicates a significant capital raise, which can be a positive sign but also carries inherent risks associated with market reception and the company's ability to execute its growth strategy.

Key Numbers

• $300.0M — Proposed Stock Offering (Maximum aggregate amount Cosmos Health Inc. intends to raise through the sale of common stock.)
• 23346023 — Revenue (Represents revenue for a specific period, likely a fiscal year or quarter, as detailed in the filing.)
• 23259526 — Cost of Revenue (Corresponds to the cost of goods sold for the period related to the revenue figure.)

Key Players & Entities

• Cosmos Health Inc. (company) — Filer of the S-1 registration statement.
• $300 million (dollar_amount) — Proposed maximum aggregate offering price of common stock.
• Cosmos Holdings Inc. (company) — Former name of Cosmos Health Inc.
• Prime Estates & Developments Inc (company) — Another former name of Cosmos Health Inc.
• Nevada (state) — State of incorporation for Cosmos Health Inc.

FAQ

Key Financial Figures

• $0.703 — Stock on the Nasdaq Capital Market was $0.703 per share. We are also offering on a "
• $0 — Stock to be sold in this offering minus $0.001, the exercise price per share of Co
• $40,202,238 — er 30, 2024, the Company had revenue of $40,202,238, a net loss of $6,639,935 and net cash
• $6,639,935 — d revenue of $40,202,238, a net loss of $6,639,935 and net cash used in operations of $3,8
• $3,883,215 — ,935 and net cash used in operations of $3,883,215. Additionally, as of September 30, 2024
• $11,027,653 — Company had positive working capital of $11,027,653, an accumulated deficit of $104,479,192
• $104,479,192 — $11,027,653, an accumulated deficit of $104,479,192, and stockholders' equity of $34,976,59
• $34,976,599 — 04,479,192, and stockholders' equity of $34,976,599. It is management's opinion that these
• $1.00 — the Company's common stock of at least $1.00 per share for ten (10) consecutive trad

Filing Documents

• cosm_s1.htm (S-1) — 4134KB
• cosm_ex11.htm (EX-1.1) — 55KB
• cosm_ex48.htm (EX-4.8) — 97KB
• cosm_ex49.htm (EX-4.9) — 88KB
• cosm_ex1097.htm (EX-10.97) — 207KB
• cosm_ex231.htm (EX-23.1) — 3KB
• cosm_ex232.htm (EX-23.2) — 4KB
• cosm_ex107.htm (EX-FILING FEES) — 52KB
• cosm_ex232img4.jpg (GRAPHIC) — 2KB
• cosm_s1img4.jpg (GRAPHIC) — 3KB
• cosm_s1img3.jpg (GRAPHIC) — 7KB
• cosm_ex232img3.jpg (GRAPHIC) — 7KB
• cosm_ex231img2.jpg (GRAPHIC) — 3KB
• 0001477932-24-008191.txt ( ) — 16807KB
• cosm-20240930.xsd (EX-101.SCH) — 141KB
• cosm-20240930_lab.xml (EX-101.LAB) — 744KB
• cosm-20240930_cal.xml (EX-101.CAL) — 91KB
• cosm-20240930_pre.xml (EX-101.PRE) — 654KB
• cosm-20240930_def.xml (EX-101.DEF) — 456KB
• cosm_s1_htm.xml (XML) — 2900KB

RISK FACTORS

RISK FACTORS 13 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 30

USE OF PROCEEDS

USE OF PROCEEDS 31 DIVIDEND POLICY 31 CAPITALIZATION 32

DILUTION

DILUTION 33 MARKET PRICE OF OUR COMMON STOCK 33

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 34

BUSINESS

BUSINESS 53 MANAGEMENT 63 PRINCIPAL SHAREHOLDERS 71 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 72 DESCRIPTION OF SHARE CAPITAL 73 DESCRIPTION OF COMMON WARRANTS TO BE ISSUED AS PART OF THE OFFERING 73 PLAN OF DISTRIBUTION 76 LEGAL MATTERS 79 EXPERTS 79 WHERE YOU CAN FIND ADDITIONAL INFORMATION 79 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 3 Table of Contents We have not authorized anyone to give any information or to make any representation other than those contained in this prospectus. You must not rely upon any information or representation not contained in this prospectus (as supplemented or amended) as having been authorized by us. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy our securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus (as supplemented or amended) is accurate on any date subsequent to the date set forth on the front of the document, even though this prospectus (as supplemented or amended) is delivered, or securities are sold, on a later date. Unless otherwise indicated or the context otherwise requires, all references in this prospectus to the terms "Cosmos Health," "Cosmos Health," the "Company," "us," "we", "our" and the "Registrant" refer to Cosmos Health Inc., a Nevada corporation, and its consolidated subsidiaries. For investors outside the United States: We have not done anything that would permit the offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the Un

View Full Filing

View this S-1 filing on SEC EDGAR